XNCR Q3 2024 Earnings — Xencor, Inc. Revenue & Financial Results | Market Cap Arena

XNCRXencor, Inc.

$890M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M-69.9% YoY

Gross Profit

$18M100.0% margin

Operating Income

-$55M-310.2% margin

Net Income

-$46M-260.1% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

+4.9%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$28M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$984M

Total Liabilities

$263M

Stockholders' Equity

$724M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$59M	-69.9%
Gross Profit	$18M	-$6M	+408.0%
Operating Income	-$55M	-$18M	-202.1%
Net Income	-$46M	-$24M	-90.7%

Revenue Segments

Non-cash Royalty

$11M100%